• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向热休克因子1破坏慢性淋巴细胞白血病中热休克蛋白90的伴侣功能。

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.

作者信息

Ganguly Siddhartha, Home Trisha, Yacoub Abdulraheem, Kambhampati Suman, Shi Huidong, Dandawate Prasad, Padhye Subhash, Saluja Ashok K, McGuirk Joseph, Rao Rekha

机构信息

The University of Kansas Cancer Center, Kansas City, KS, USA.

Georgia Regents University, Augusta, GA, USA.

出版信息

Oncotarget. 2015 Oct 13;6(31):31767-79. doi: 10.18632/oncotarget.5167.

DOI:10.18632/oncotarget.5167
PMID:26397138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4741638/
Abstract

CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton's Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec-1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.

摘要

慢性淋巴细胞白血病(CLL)是一种以染色体缺失、获得性拷贝数改变和非整倍体为特征的疾病。最近的研究表明,非整倍体肿瘤细胞中热休克因子(HSF)1的过表达可以克服热休克蛋白(HSP)90介导的蛋白质折叠缺陷并恢复蛋白质稳态。有趣的是,几项独立研究表明,HSF1的表达和活性也会影响HSP90激酶客户蛋白的伴侣功能,尽管这一现象背后的机制尚不清楚。在此,我们以CLL作为模型系统,确定了HSF1如何调节HSP90的功能。我们报告称,HSF1在CLL中过表达,雷公藤内酯醇(一种HSF1的小分子抑制剂)处理可诱导培养的和原代CLL B细胞凋亡。我们证明,敲低HSF1或用雷公藤内酯醇抑制HSF1会导致HSP90与其激酶共伴侣细胞分裂周期37(CDC37)的结合减少,从而导致HSP90客户激酶布鲁顿酪氨酸激酶(BTK)、c-RAF和细胞周期蛋白依赖性激酶4(CDK4)部分耗竭。用雷公藤内酯醇处理或敲低HSF1会破坏HSF1、p97、HSP90和HSP90去乙酰化酶——组蛋白去乙酰化酶6(HDAC6)之间的胞质复合物。因此,抑制HSF1会导致HSP90乙酰化并消除其伴侣功能。最后,将Mec-1细胞尾静脉注射到Rag2-/-IL2Rγc-/-小鼠体内,随后用雷公藤内酯醇的前体药物米内立德进行处理,可减少白血病、提高生存率并减弱体内HSP90依赖性生存信号。总之,我们的研究为靶向HSF1以及测试米内立德对人类CLL的活性提供了有力的理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/3996affc9004/oncotarget-06-31767-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/69d486f61e73/oncotarget-06-31767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/443060699612/oncotarget-06-31767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/9152b3ffbc06/oncotarget-06-31767-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/47b07ff61f22/oncotarget-06-31767-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/24dbe36f3b6b/oncotarget-06-31767-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/89b364cca9e4/oncotarget-06-31767-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/3996affc9004/oncotarget-06-31767-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/69d486f61e73/oncotarget-06-31767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/443060699612/oncotarget-06-31767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/9152b3ffbc06/oncotarget-06-31767-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/47b07ff61f22/oncotarget-06-31767-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/24dbe36f3b6b/oncotarget-06-31767-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/89b364cca9e4/oncotarget-06-31767-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8126/4741638/3996affc9004/oncotarget-06-31767-g007.jpg

相似文献

1
Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.靶向热休克因子1破坏慢性淋巴细胞白血病中热休克蛋白90的伴侣功能。
Oncotarget. 2015 Oct 13;6(31):31767-79. doi: 10.18632/oncotarget.5167.
2
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.热休克转录因子 1 作为多发性骨髓瘤潜在的新治疗靶点。
Br J Haematol. 2013 Feb;160(4):465-76. doi: 10.1111/bjh.12164. Epub 2012 Dec 18.
3
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.靶向热休克因子1可使癌细胞对热休克蛋白90抑制敏感。
Oncotarget. 2013 Jun;4(6):816-29. doi: 10.18632/oncotarget.991.
4
HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.HER2/ErbB2 激活 HSF1,从而控制 HSP90 客户,包括 HER2 过表达乳腺癌中的 MIF。
Cell Death Dis. 2014 Jan 2;5(1):e980. doi: 10.1038/cddis.2013.508.
5
HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.热休克蛋白90(HSP90)在多客户相互作用组中稳定B细胞受体激酶:PU-H71在细胞保护微环境中诱导慢性淋巴细胞白血病(CLL)细胞凋亡。
Oncogene. 2017 Jun 15;36(24):3441-3449. doi: 10.1038/onc.2016.494. Epub 2017 Jan 23.
6
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.ROR1 失稳增强伊布替尼对体内慢性淋巴细胞白血病的活性。
Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.
7
Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.热休克因子 1 是治疗成人 T 细胞白血病的有希望的治疗靶点。
Med Oncol. 2023 May 10;40(6):172. doi: 10.1007/s12032-023-02042-5.
8
Identification of inhibitors of HSF1 functional activity by high-content target-based screening.通过基于靶点的高内涵筛选鉴定热休克因子1功能活性抑制剂。
J Biomol Screen. 2009 Dec;14(10):1165-75. doi: 10.1177/1087057109347472.
9
Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.鉴定混合谱系白血病1(MLL1)蛋白作为热休克因子1(HSF1)蛋白在热休克蛋白90(HSP90)抑制反应中的共激活因子。
J Biol Chem. 2014 Jul 4;289(27):18914-27. doi: 10.1074/jbc.M114.574053. Epub 2014 May 15.
10
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.组蛋白去乙酰化酶6的抑制作用使热休克蛋白90乙酰化并破坏其伴侣功能:组蛋白去乙酰化酶抑制剂抗白血病活性的新基础。
J Biol Chem. 2005 Jul 22;280(29):26729-34. doi: 10.1074/jbc.C500186200. Epub 2005 Jun 2.

引用本文的文献

1
HDAC6 modulates the cognitive behavioral function and hippocampal tissue pathological changes of APP/PS1 transgenic mice through HSP90-HSF1 pathway.组蛋白去乙酰化酶 6 通过热休克蛋白 90-热休克因子 1 通路调节 APP/PS1 转基因小鼠的认知行为功能和海马组织病理变化。
Exp Brain Res. 2024 Aug;242(8):1983-1998. doi: 10.1007/s00221-024-06858-z. Epub 2024 Jun 27.
2
The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression.小分子药物高三尖杉酯碱靶向热休克因子1以抑制胰腺癌进展。
Am J Cancer Res. 2024 May 15;14(5):2072-2087. doi: 10.62347/XFJH3424. eCollection 2024.
3
The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics.

本文引用的文献

1
HSF1 deficiency and impaired HSP90-dependent protein folding are hallmarks of aneuploid human cells.热休克因子1缺乏和热休克蛋白90依赖性蛋白折叠受损是非整倍体人类细胞的特征。
EMBO J. 2014 Oct 16;33(20):2374-87. doi: 10.15252/embj.201488648. Epub 2014 Sep 9.
2
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
3
Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells.
热休克蛋白与癌症发病机制之间的相互作用:一种癌症治疗的新策略。
Cancers (Basel). 2024 Feb 1;16(3):638. doi: 10.3390/cancers16030638.
4
Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy.利用中药单体和复方制剂的力量增强癌症免疫疗法。
Front Immunol. 2023 Nov 15;14:1277243. doi: 10.3389/fimmu.2023.1277243. eCollection 2023.
5
Heat Shock Factor 1 Inhibition: A Novel Anti-Cancer Strategy with Promise for Precision Oncology.热休克因子1抑制:一种有望用于精准肿瘤学的新型抗癌策略。
Cancers (Basel). 2023 Oct 27;15(21):5167. doi: 10.3390/cancers15215167.
6
HSP90 Exacerbates Bone Destruction in Rheumatoid Arthritis by Activating TRAF6/NFATc1 Signaling.HSP90 通过激活 TRAF6/NFATc1 信号加重类风湿关节炎中的骨破坏。
Inflammation. 2024 Feb;47(1):363-375. doi: 10.1007/s10753-023-01914-2. Epub 2023 Oct 30.
7
HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation.组蛋白去乙酰化酶 6 抑制:有望转化为肾移植临床实践的重要潜在调控因子和治疗选择。
Front Immunol. 2023 Jul 21;14:1168848. doi: 10.3389/fimmu.2023.1168848. eCollection 2023.
8
Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.热休克因子 1 是治疗成人 T 细胞白血病的有希望的治疗靶点。
Med Oncol. 2023 May 10;40(6):172. doi: 10.1007/s12032-023-02042-5.
9
Targeting HSF1 for cancer treatment: mechanisms and inhibitor development.靶向 HSF1 治疗癌症:机制与抑制剂开发。
Theranostics. 2023 Apr 17;13(7):2281-2300. doi: 10.7150/thno.82431. eCollection 2023.
10
HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia.HSF1 是急性髓系白血病中白血病干细胞自我更新的驱动因子。
Nat Commun. 2022 Oct 16;13(1):6107. doi: 10.1038/s41467-022-33861-1.
雷公藤内酯醇激活未折叠蛋白反应,导致胰腺癌细胞慢性内质网应激。
Am J Physiol Gastrointest Liver Physiol. 2014 Jun 1;306(11):G1011-20. doi: 10.1152/ajpgi.00466.2013. Epub 2014 Apr 3.
4
Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.雷公藤内酯醇增强了胰腺癌对 TRAIL 诱导的死亡受体途径的激活作用。
Cancer Lett. 2014 Jun 28;348(1-2):156-66. doi: 10.1016/j.canlet.2014.03.016. Epub 2014 Mar 21.
5
Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102.三尖杉酯碱衍生物 MRx102 的临床前抗白血病活性、毒理学、毒代动力学和制剂开发。
Cancer Chemother Pharmacol. 2014 May;73(5):961-74. doi: 10.1007/s00280-014-2428-6. Epub 2014 Mar 12.
6
Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.慢性淋巴细胞白血病患者与50000多名准正常参与者相比的获得性染色体异常。
Cancer Genet. 2014 Jan-Feb;207(1-2):19-30. doi: 10.1016/j.cancergen.2014.01.004. Epub 2014 Jan 17.
7
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.金诺芬诱导致命的氧化应激和内质网应激,并对慢性淋巴细胞白血病发挥强大的临床前活性。
Cancer Res. 2014 May 1;74(9):2520-32. doi: 10.1158/0008-5472.CAN-13-2033. Epub 2014 Mar 5.
8
HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.HER2/ErbB2 激活 HSF1,从而控制 HSP90 客户,包括 HER2 过表达乳腺癌中的 MIF。
Cell Death Dis. 2014 Jan 2;5(1):e980. doi: 10.1038/cddis.2013.508.
9
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).布鲁顿酪氨酸激酶(BTK)的功能对慢性淋巴细胞白血病(CLL)的发展和扩张很重要。
Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.
10
Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.雷公藤红素诱导的胰腺癌细胞死亡是由转录因子 Sp1 的 O-GlcNAc 修饰介导的。
J Biol Chem. 2013 Nov 22;288(47):33927-33938. doi: 10.1074/jbc.M113.500983. Epub 2013 Oct 15.